{"id":"ciclesonide-hfa","safety":{"commonSideEffects":[{"rate":null,"effect":"Pharyngitis"},{"rate":null,"effect":"Nasal congestion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Upon inhalation, ciclesonide is converted by esterases in the airway epithelium to des-ciclesonide, which then binds to intracellular glucocorticoid receptors, modulating the transcription of genes involved in inflammation.","oneSentence":"Ciclesonide is a prodrug that is converted to its active metabolite, des-ciclesonide, which binds to glucocorticoid receptors in the cytoplasm, leading to anti-inflammatory effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:26:52.328Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT00458835","phase":"PHASE4","title":"Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)","status":"COMPLETED","sponsor":"Covis Pharma S.à.r.l.","startDate":"2007-04","conditions":"Allergic Rhinitis","enrollment":30},{"nctId":"NCT00384189","phase":"PHASE3","title":"A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Asthma","enrollment":1080},{"nctId":"NCT00807053","phase":"PHASE2","title":"Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-04","conditions":"Rhinitis, Allergic, Seasonal","enrollment":480},{"nctId":"NCT00659048","phase":"PHASE3","title":"Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Rhinitis, Allergic, Perennial","enrollment":106},{"nctId":"NCT00790023","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-11","conditions":"Seasonal Allergic Rhinitis","enrollment":707},{"nctId":"NCT01287364","phase":"PHASE3","title":"Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-02","conditions":"Perennial Allergic Rhinitis","enrollment":185},{"nctId":"NCT01033825","phase":"PHASE3","title":"Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-01","conditions":"Perennial Allergic Rhinitis","enrollment":310},{"nctId":"NCT01067105","phase":"PHASE3","title":"A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-02","conditions":"Perennial Allergic Rhinitis","enrollment":824},{"nctId":"NCT00953147","phase":"PHASE3","title":"A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-08","conditions":"Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":1110},{"nctId":"NCT01010971","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-12","conditions":"Seasonal Allergic Rhinitis","enrollment":671},{"nctId":"NCT00254956","phase":"PHASE3","title":"Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-01","conditions":"Respiratory Tract Diseases, Respiratory Hypersensitivity, Asthma","enrollment":1568}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Ciclesonide HFA","genericName":"Ciclesonide HFA","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ciclesonide is a prodrug that is converted to its active metabolite, des-ciclesonide, which binds to glucocorticoid receptors in the cytoplasm, leading to anti-inflammatory effects. Used for Asthma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}